Patrícia Oliveira, Biochemist and PhD in Basic and Applied Biology
Currently Patrícia is a Post-Doc researcher in the Expression Regulation in Cancer group (led by Carla Oliveira) at IPATIMUP. During the last 5 years Patrícia has gathered several skills in bioinformatics analysis and meta-analysis using several databases such as Ensembl, NCBI and UCSC. Patrícia is also knowledgeable in PERL programming, R statistics, Biomart-based data mining, as well as experienced in using several other on-line databases (such as InterPro and AmiGO) and softwares, such as IPA (Ingenuity Systems Pathway Analysis) and DAVID (Database for Annotation, Visualization and Integrated Discovery). In addition, Patrícia is also experienced in data analysis derived from Microarray experiments (both basic gene expression and tiling array experiments) as well as data analysis from Whole Genome Sequencing (DNAseq) and Whole Transcriptome Sequencing (RNAseq). Concurrently, Patrícia has been providing bioinformatics support to several national and international groups within collaborative projects.
Currently Patrícia is a Post-Doc researcher in the Expression Regulation in Cancer group (led by Carla Oliveira) at IPATIMUP. During the last 5 years Patrícia has gathered several skills in bioinformatics analysis and meta-analysis using several databases such as Ensembl, NCBI and UCSC. Patrícia is also knowledgeable in PERL programming, R statistics, Biomart-based data mining, as well as experienced in using several other on-line databases (such as InterPro and AmiGO) and softwares, such as IPA (Ingenuity Systems Pathway Analysis) and DAVID (Database for Annotation, Visualization and Integrated Discovery). In addition, Patrícia is also experienced in data analysis derived from Microarray experiments (both basic gene expression and tiling array experiments) as well as data analysis from Whole Genome Sequencing (DNAseq) and Whole Transcriptome Sequencing (RNAseq). Concurrently, Patrícia has been providing bioinformatics support to several national and international groups within collaborative projects.
Carla Oliveira, Biochemist and PhD in Human Biology
Currently, Carla is Head of the Expression Regulation in Cancer group at IPATIMUP as well as a consultant of IPATIMUP Diagnostics and an Affiliated Professor of Biopathology at the Faculty of Medicine of the University of Porto. Carla is an International Expert in E-cadherin-related diseases namely hereditary diffuse gastric cancer (HDGC), belonging to the International Gastric Cancer Linkage Consortium. With higher education in UK, Canada and Germany, Carla started her own research program in 2005 at IPATIMUP, became a Junior Group Leader in 2008 (Ciência 2007), obtained tenure in 2011 and a Group Leader position in 2013. Carla has disclosed molecular and clinical aspects of worldwide series of families and sporadic gastric cancer cases, found novel germline CDH1 genetic defects, defined somatic events with impact for patient management and therapy, and reported an association between germline CDH1 mutations and developmental malformations. A major and transversal interest of Carla’s group is the definition and validation of germline causative defects in cancer-associated syndromes using Next Generation Sequencing platforms. In fact, Carla’s group has been using both large- and small-scale genomics and transcriptomics approaches, on a regular basis, to test clinically relevant hypothesis, and validate in vitro data. Carla's long-term goal is to shed light into the regulation of key genes during cancer progression and thus finding targets for clinical intervention.
Currently, Carla is Head of the Expression Regulation in Cancer group at IPATIMUP as well as a consultant of IPATIMUP Diagnostics and an Affiliated Professor of Biopathology at the Faculty of Medicine of the University of Porto. Carla is an International Expert in E-cadherin-related diseases namely hereditary diffuse gastric cancer (HDGC), belonging to the International Gastric Cancer Linkage Consortium. With higher education in UK, Canada and Germany, Carla started her own research program in 2005 at IPATIMUP, became a Junior Group Leader in 2008 (Ciência 2007), obtained tenure in 2011 and a Group Leader position in 2013. Carla has disclosed molecular and clinical aspects of worldwide series of families and sporadic gastric cancer cases, found novel germline CDH1 genetic defects, defined somatic events with impact for patient management and therapy, and reported an association between germline CDH1 mutations and developmental malformations. A major and transversal interest of Carla’s group is the definition and validation of germline causative defects in cancer-associated syndromes using Next Generation Sequencing platforms. In fact, Carla’s group has been using both large- and small-scale genomics and transcriptomics approaches, on a regular basis, to test clinically relevant hypothesis, and validate in vitro data. Carla's long-term goal is to shed light into the regulation of key genes during cancer progression and thus finding targets for clinical intervention.
Genetest
Genetest is a spin-off of IPATIMUP, and with it maintains close collaboration with regards to investigation and development. It was created in 2004 and includes PME Capital and the Lena Group and is a part of the business incubator programme at BioCodex – Incubator for Life Sciences Businesses Corp. Genetest’s main undertaking is the investigation of genetic susceptibility of illnesses through testing and was the first laboratory in Portugal to present an extensive range of genetic tests in cardiology which has made it possible to diagnose a series of cardiovascular pathologies with an associated genetic component. Genetest’s laboratories are located at the IPATIMUP facilities. Our team is made up of specialized technicians and doctorates in a variety of scientific fields. Genetest, in partnership with IPATIMUP, has developed an innovative new saliva testing method for diagnosis of cardiovascular and gastroenterology illnesses. The sample is collected by scaling epithelial cells of the mouth by means of a supplied kit through which DNA is extracted for analysis. For more information visit Genetest website at www.genetest.pt.
Genetest is a spin-off of IPATIMUP, and with it maintains close collaboration with regards to investigation and development. It was created in 2004 and includes PME Capital and the Lena Group and is a part of the business incubator programme at BioCodex – Incubator for Life Sciences Businesses Corp. Genetest’s main undertaking is the investigation of genetic susceptibility of illnesses through testing and was the first laboratory in Portugal to present an extensive range of genetic tests in cardiology which has made it possible to diagnose a series of cardiovascular pathologies with an associated genetic component. Genetest’s laboratories are located at the IPATIMUP facilities. Our team is made up of specialized technicians and doctorates in a variety of scientific fields. Genetest, in partnership with IPATIMUP, has developed an innovative new saliva testing method for diagnosis of cardiovascular and gastroenterology illnesses. The sample is collected by scaling epithelial cells of the mouth by means of a supplied kit through which DNA is extracted for analysis. For more information visit Genetest website at www.genetest.pt.
